Effectiveness of Maintenance Treatment with Tiotropium + Olodaterol in Comparison to Inhaled Corticosteroids + Long-acting β2 agonists in COPD patients in Taiwan: a non-interventional study based on the Taiwan National Health Insurance (NHI) data. (1237-0110)

Study identification

• EU PAS number:
  EUPAS47389
• Study ID:
  49767
• Official title and acronym:
  Effectiveness of Maintenance Treatment with Tiotropium + Olodaterol in Comparison to Inhaled Corticosteroids + Long-acting β2 agonists in COPD patients in Taiwan: a non-interventional study based on the Taiwan National Health Insurance (NHI) data. (1237-0110)
• DARWIN EU® study:
  No
• Study countries:
  China
• Study description:
  To compare the risk of exacerbations between initiators of Tiotropium / Olodaterol (Tio/Olo) and inhaled corticolsteroids / long-acting β2-agonists (ICS/LABA) in a real world setting
• Study status:
  Planned

Study timelines

Date when funding contract was signed

Planned:17/06/2021

Actual:17/06/2021

Study start date

Planned:15/08/2022

Date of final study report

Planned:03/07/2023

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Boehringer Ingelheim (China) Investment Co., Ltd

Regulatory

• Was the study required by a regulatory body?:
  Unknown
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable